Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05390515 · ClinicalTrials.gov registry record · Phase 4
Psoriatic Immune Response to Tildrakizumab
A Phase 4 study, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT05390515: Recruiting Phase 4 study, sponsored by University of California, San Francisco.
NCT05390515 is a Phase 4 study that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 10 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05390515, a Phase 4 study, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.
Primary Outcome
Change in severity and extent of psoriasis (calculated by Psoriasis Area and Severity Index (PASI) score); scale range of 0 to 72, 72 being maximal disease.
Interventions
- DRUG Tildrakizumab Prefilled Syringe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-09-01 |
| Est. Completion | 2028-09-01 |
| Phase | Phase 4 |
What NCT05390515 shows while recruiting
NCT05390515 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Tildrakizumab Prefilled Syringe is the first listed.
NCT05390515 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05390515 about?
NCT05390515 is a clinical study titled "Psoriatic Immune Response to Tildrakizumab". This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.
What is the current status of trial NCT05390515?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2022-09-01. Estimated completion is 2028-09-01.
What interventions are being tested in trial NCT05390515?
The interventions under investigation include: Tildrakizumab Prefilled Syringe (DRUG).
Who is sponsoring clinical trial NCT05390515?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05390515's enrollment target sits among peer trials
10 1940th of 2000 higher than 33 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI